drugset
Drugs / Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine
last change Dec 2023 re-read 3 minutes ago

Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine

also known as nOPV3

Vaccine

Developed for
poliomyelitis
Investigated by
Bill and Melinda Gates Foundation · Centers for Disease Control and Prevention · PATH · PT Bio Farma · Technical Resources International, Inc.

Trials 1

today NCT05654467 · Ph 2
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05654467 Dec 2023 → Mar 2027 expected poliomyelitis PATH Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05654467 ↗
Known as nOPV3 “Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)” NCT05654467 ↗
Modality Vaccine “novel oral polio type 3 vaccine” NCT05654467 ↗
Route Oral “novel oral polio type 3 vaccine” NCT05654467 ↗